Journal of Chemical Metrology Articles

This study aimed to establish and validate a reliable RP-HPLC assay method for the quantification of tofacitinib (TFC), a janus kinase (JAK) inhibitor, in pharmaceutical formulations. The newly developed method exhibits simplicity, specificity, precision, and sensitivity. Experimental procedures utilized a Shimadzu Prominence 20A HPLC system equipped with a Inertsil ODS 3V C18 column (5µm particle size, 4.6 X 250 mm dimensions). The mobile phase, consisting of 0.05M ammonium acetate buffer at pH 5.0 and acetonitrile (65:35 v/v) in isocratic mode with a flow rate of 1.0 mL/min, facilitated accurate detection of the Tofacitinib peak at 230 nm wavelength. Comprehensive validation, including assessments of linearity,  accuracy, precision, and robustness, was conducted in accordance with ICH requirements. The results demonstrated satisfaction, with a retention time (tR) of approximately 5.3 minutes. The imperative need for a swift and efficient RP-HPLC method for analyzing TFC led to the successful development and validation of this technique. Consequently, the RP-HPLC method has undergone thorough validation, establishing it as a user-friendly and trustworthy means for Tofacitinib analysis.

The hypoxia inducible factor prolyl hydroxylase inhibitor Desidustat is used to treat anemia linked to chronic kidney disease (CKD). For the estimation of Desidustat in bulk and commercial tablet formulation known as Oxemia, a precise, accurate, and sensitive reverse phase HPLC method has been developed and validated. The method described here was optimised with a Hypersil C18 (250 × 4.6 mm, 5 µm) column serving as the stationary phase and a mobile phase that included methanol: acetonitrile (80:20 v/v) added to the column at a flow rate of 1 mL/min. Using a photo diode array detector, Desidustat was detected at an analytical wavelength of 230 nm. With a correlation coefficient of 0.9989, the developed method was found to be linear in the concentration range of 1–6 µg/mL. Every parameter listed in the in International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Quality 2 (Revision 1) guideline was verified for the described method.

Measurement uncertainty is a metrological concept that characterizes distributions/variations that can make the measurement results logical and is linked to the result of the measurement. The measurement uncertainty of the method was estimated using two basic approaches (top-down and bottom-up approach). The top-down approach covers in-house validation data (trueness, repeatability and intra-lab reproducibility), while the bottom-up approach involves individual contributions to all uncertainty at each stage of the analysis/process. We estimated measurement uncertainty of BPA analysis by HPLC-FLD test according to JCGM GUM and EURACHEM-CITAC guidelines. The relative expanded uncertainties at the BPA concentration by the bottom-up approach and top-down approaches were ±3.2% and ±4.8% respectively (95% confidence interval, k=2). Thus, although it is seen that the results of the two approaches are different in chromatographic BPA analysis, it is concluded that the measurement uncertainty related to BPA analysis, especially in food analysis laboratories, can be determined by a simpler top-down approach.

In a Quality by Design (QbD) approach, the impact and interaction of critical variables are understood and optimized using Design of Experiment (DoE). DoE includes statistical multivariate analysis and modeling of data for continuous improvement of method. In present research work 24 full factorial design was applied to optimize and select appropriate chromatographic condition for the RP-HPLC method development of Torsemide (TOR) and Spironolactone (SPI) in synthetic mixture. The drug was analyzed using a LiChrospher® C 18 (5µm, 250×4 mm) and a mobile phase of acetonitrile: buffer (57.4:42.6 v/v) at a flow rate of 1 mL/min, with TOR showing considerable absorbance at 290 nm and SPI showing significant absorbance at 238 nm. For TOR and SPI, the technique was shown to be linear over the concentration range of 2–12 μg/mL and 10–60 μg/mL, respectively. LOD and LOQ values for TOR were 0.10 g/mL and 0.32 g/mL, respectively, whereas those for SPI were 0.75 µg/mL and 2.29 µg/mL. The correlation coefficient (R2) was found 0.9973 for TOR and 0.9976 for SPI. Recovery study for accuracy was found in the range of 97.55 % - 99.05% and 94.82%-100% for TOR and SPI respectively.

Simple, accurate, precise, and sensitive reverse-phase high-performance liquid chromatographic (HPLC) method was developed for the simultaneous measurement of ARI and ESC in pharmaceutical products by using a C18 column with dimensions of 250 mm x 4.6 mm and a particle size of 5 μm. The mobile phase consisted of a mixture of acetonitrile, methanol, and water in the ratio of 80:05:15 v/v/v. Orthophosphoric acid was added to adjust the pH to 7.00 ± 0.1. The detection wavelength used for measuring the absorbance of the components was 246 nm, and the Mobile Phase flow rate was set at 1.0 mL/min. The retention times of ARI and ESC were 5.63 and 3.65 minutes, respectively. The ARI and ESC correlation coefficients (R2-values) were observed at 0.9995 and 0.9997, respectively, demonstrating a robust linear relationship between the analyte concentration and the observed absorbance. The linearity range for ARI was 20 to 120 μg/mL, while ESC was 60 to 360 μg/mL. The recovery percentages for ARI and ESC ranged from 99.43% to 100.65% and 99.58% to 100.15%, respectively. Additionally, all parameter uncertainty levels were below 2. The method was validated following ICH guideline Q2 (R1). The analytical method validated will be successfully applied to the pharmaceutical dosage form.

For sachet drug forms containing Racecadotril, which are freely soluble in methanol and methylene chloride but practically insoluble in water, used as an anti-diarrhea, suitable dissolution media meeting the parameters requested by the authorities are not available in the literature and monographs. For this reason, a suitable dissolution medium was determined in accordance with the guidelines and the dissolution profiles of reference product and samples used in the study. The profiles were compared, and the method was validated. In order to determine the most suitable medium for the release of drug product, in vitro dissolution tests were performed in media prepared by different buffers similar to the pH of the gastrointestinal tract (GIT) and media containing Brij 35.  In this context, the effects of buffers, pH, and different surfactants were evaluated, and it was found that Polyoxyethylene 23 lauryl ether (Brij-35), a nonionic surfactant, increased the solubility. The results were obtained with RP-HPLC method using Kromasil C18 150 mm x 4.6 mm, 5 µm column with a flow rate of 1.5 ml/min at 210 nm wavelength in 7 minutes for Racecadotril, which dissolves at least 60% of the label value after 45 minutes after the dissolution studies performed with a type II apparatus at 37°C.  A suitable dissolution medium was found for sachet drug forms containing Racecadotril, and the analytical method was validated in accordance with the ICH Q2 (R1) guideline. In addition, the difference factor (f1) and similarity factor (f2) were calculated to compare the dissolution profiles of the reference product and samples in this determined dissolution medium.